

Autoantibodies in twins discordant for rheumatoid arthritis

Rheumatoid arthritis (RA) is characterised by frequent occurrence of autoantibodies. The anti-cyclic citrullinated peptide antibodies (anti-CCP) are now used routinely as they may antedate the development of seropositive RA, because their diagnostic sensitivity and specificity is better than rheumatoid factors (RFs), and because they may predict a more severe outcome.¹⁻³ Previous studies have observed an increased prevalence of RF and anti-CCP in first-degree relatives of patients with RA.⁴ One study on RA discordant twin pairs provided evidence for genetic effects on IgM-RF and IgG-RF independent of HLA-DR.⁵ Anti-CCPs have been reported to be independently associated with the HLA-DRB1 shared epitope, PTPN22 and smoking,⁶ and there is strong evidence for a link between anti-CCP and smoking.^{7,8}

We wished to examine if the occurrence of selected autoantibodies in RA is attributable to shared genetic and/or environmental factors. For this purpose we performed a co-twin control study including both monozygotic (MZ) and dizygotic (DZ) RA discordant twin pairs. This design corresponds to a

matched case-control study, where the RA affected twin in each pair is the case while the unaffected co-twin serves as control. The presence of an autoantibody is the exposure and RA the outcome. Only pairs discordant for exposure contribute to the conditional logistic regression analysis performed separately for the MZ and the DZ pairs.

This design enabled us to stratify for the effect of age and sex in DZ pairs and for genes as well in MZ pairs.

Thus, if RA and autoantibody production have a shared environmental background, the odds ratio (OR) for the autoantibody in MZ twins would significantly exceed that of DZ twins since genetic variability is eliminated in MZ pairs. Conversely, if shared genetic factors are involved a significantly higher OR in DZ twins than in MZ twins would be expected.

Twelve monozygotic and 32 dizygotic RA discordant twin pairs from a previously published twin study⁹ were tested for the presence of IgM-RF and IgA-RF, antikeratin antibodies and anti-CCP antibodies. The results are presented in table 1.

The OR was >1 for all four autoantibodies in either zygosity group in accordance with the well-established relationship between these autoantibodies and RA, but in the MZ group statistical significance was only reached for anti-CCP antibodies. Since there is no genetic variation within MZ twin pairs it

Table 1 Number of RA discordant pairs by antibodies and zygosity

Antibody	Zygosity group	Antibody-positive RA twins with a non-RA antibody-negative co-twin	Antibody-positive non-RA twin with an RA antibody-negative co-twin	OR for RA (95% CI) according to presence or absence of antibody		Ratio DZ/MZ ORs
AKA	DZ	14	0	179.4	(3.6 to 591.9)	46
	MZ	3	1	3.9	(0.5 to 17.8)	
CCP	DZ	15	0	290.0	(3.9 to 622.0)	2
	MZ	6	0	146.1	(1.4 to 281.6)	
IgA-RF	DZ	16	0	204.5	(4.1 to 660.8)	29
	MZ	6	1	7.0	(0.9 to 30.4)	
IgM-RF	DZ	18	2	9.5	(2.3 to 32.1)	3
	MZ	7	2	3.0	(0.8 to 13.0)	

Owing to cells with zero observations, OR and 95% plausibility intervals are estimated from standard Bayesian techniques (assuming a Dirichlet-multinomial distribution of probabilities of counts).¹⁰

AKA, antikeratin antibody; CCP, cyclic citrullinated peptide; DZ, dizygotic; MZ, monozygotic; RA, rheumatoid arthritis; RF, rheumatoid factor.

follows that there must be an underlying environmental covariation between the occurrence of these autoantibodies and RA. Furthermore, for all four antibodies OR was higher in DZ than in MZ twins, suggesting an additional underlying genetic covariation between these antibodies and RA, particularly for antikeratin antibody and IgA-RF. The already established association between the shared epitope and anti-CCP-positive RA suggests that variation of the shared epitope within DZ discordant pairs may explain the higher OR for anti-CCP in DZ twins.

In conclusion, this first study on anti-CCP and antikeratin in twins suggests that both environmental and genetic effects may influence the expression of these autoantibodies.

A J Svendsen,¹ J V Hjelmborg,² A Wiik,³ G Houen,³ K O Kyvik,^{1,4} P Junker⁵

¹The Danish Twin Registry, Institute of Public Health, University of Southern Denmark, Denmark; ²Epidemiology and Statistics, Institute of Public Health, University of Southern Denmark, Denmark; ³Department of Clinical Biochemistry and Immunology, Statens Serum Institute, Copenhagen, Denmark; ⁴Institute of Regional Health Services Research, University of Southern Denmark, Denmark; ⁵Department of Rheumatology, Odense University Hospital, Odense C, Denmark

Correspondence to Dr A J Svendsen, The Danish Twin Registry, Epidemiology, Institute of Public Health, University of Southern Denmark, J.B. Winslows Vej 9B, 5000 Odense C, Denmark; asvendsen@health.sdu.dk

Funding Danish Rheumatism Association, Danish Medical Association's Research Foundation, Karen Hansens Foundation.

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the regional ethics committee of Southern Denmark.

Provenance and peer review Not commissioned; externally peer reviewed.

Accepted 11 July 2010

Published Online First 10 August 2010

Ann Rheum Dis 2011;**70**:708–709. doi:10.1136/ard.2010.132860

REFERENCES

1. Nishimura K, Sugiyama D, Kogata Y, *et al.* Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann Intern Med* 2007;**146**:797–808.
2. Nielen MM, van Schaardenburg D, Reesink HW, *et al.* Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. *Arthritis Rheum* 2004;**50**:380–6.
3. van Venrooij WJ, Zendman AJ, Puijn GJ. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. *Autoimmun Rev* 2006;**6**:37–41.
4. Koltenbach JR, Deane KD, Derber LA, *et al.* A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. *Arthritis Rheum* 2009;**61**:1735–42.
5. MacGregor AJ, Ollier WE, Venkovsky J, *et al.* Rheumatoid factor isotypes in monozygotic and dizygotic twins discordant for rheumatoid arthritis. *J Rheumatol* 1995;**22**:2203–7.
6. Morgan AW, Thomson W, Martin SG, *et al.* Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. *Arthritis Rheum* 2009;**60**:2565–76.
7. Padyukov L, Silva C, Stolt P, *et al.* A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. *Arthritis Rheum* 2004;**50**:3085–92.
8. Pedersen M, Jacobsen S, Garred P, *et al.* Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. *Arthritis Rheum* 2007;**56**:1446–53.
9. Svendsen AJ, Holm NV, Kyvik K, *et al.* Relative importance of genetic effects in rheumatoid arthritis: historical cohort study of Danish nationwide twin population. *BMJ* 2002;**324**:264–6.
10. Irony TZ, Pereira CA, Tiwari RC. Analysis of opinion swing: comparison of two correlated proportions. *Am Stat* 2000;**54**:57–62.



Autoantibodies in twins discordant for rheumatoid arthritis

A J Svendsen, J V Hjelmborg, A Wiik, et al.

Ann Rheum Dis 2011 70: 708-709 originally published online August 10, 2010

doi: 10.1136/ard.2010.132860

Updated information and services can be found at:

<http://ard.bmj.com/content/70/4/708.full.html>

These include:

References

This article cites 10 articles, 1 of which can be accessed free at:

<http://ard.bmj.com/content/70/4/708.full.html#ref-list-1>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>